Posts tagged VRX


Valeant Pharmaceuticals Intl Inc (VRX) Is Taking Reassuring Strides on Back of Strong International Segment

BTIG’s Tim Chiang notes that with various positives soaring in Valeant’s favor, these are mostly reflected in the stock’s recently climbing levels.

Valeant Pharmaceuticals Intl Inc’s (VRX) Bausch + Lomb Scores CE Mark for Ophthalmic Surgical Platform

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced this morning that its subsidiary Bausch + Lomb has received …

Louise Chen Roots for Valeant Pharmaceuticals Intl Inc (VRX) in the New Year on Back of Ocular Redness Asset’s FDA Nod

Cantor’s Louise Chen believes Valeant will surpass $8 billion in sales in 2018, and says the set-up for the rebounding giant “keeps getting better” following Lumify’s approval.

Valeant Pharmaceuticals Intl Inc (VRX) Announces Completion of Divestiture of Sprout Pharmaceuticals Subsidiary

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced that its affiliate has completed the divestiture of the …

Valeant Pharmaceuticals Intl Inc (VRX) Bear Boosts Price Target Amid Solid Turnaround Efforts

Mizuho’s Irina Rivkind Koffler cannot “justify” changing her rating on Valeant. Instead, the analyst lifts her price target by 40%; Here’s why.

Valeant Pharmaceuticals Intl Inc (VRX) Has A New Bear In Town

J.P. Morgan’s Chris Schott is raising the ultimate red flag on Valeant with a downgrade that has sent shares on a 6% dive today.

Show More